Jump to ContentJump to Main Navigation
Show Summary Details
In This Section

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.

12 Issues per year


IMPACT FACTOR 2016: 3.432

CiteScore 2016: 2.21

SCImago Journal Rank (SJR) 2015: 0.873
Source Normalized Impact per Paper (SNIP) 2015: 0.982

Online
ISSN
1437-4331
See all formats and pricing
In This Section
Volume 52, Issue 5 (May 2014)

Issues

Low serum adropin is associated with coronary atherosclerosis in type 2 diabetic and non-diabetic patients

Lingzhen Wu
  • Department of Cardiology, Fujian Medical University Union Hospital; and Fujian Institute of Coronary Heart Disease, Fuzhou, P. R. China
/ Jun Fang
  • Department of Cardiology, Fujian Medical University Union Hospital; and Fujian Institute of Coronary Heart Disease, Fuzhou, P. R. China
/ Lianglong Chen
  • Corresponding author
  • Department of Cardiology, Fujian Medical University Union Hospital, 29 Xin-Quan Road, 350001, Fuzhou, Fujian, P.R China
  • Email:
/ Ziwen Zhao
  • Department of Cardiology, Fujian Medical University Union Hospital; and Fujian Institute of Coronary Heart Disease, Fuzhou, P. R. China
/ Yukun Luo
  • Department of Cardiology, Fujian Medical University Union Hospital; and Fujian Institute of Coronary Heart Disease, Fuzhou, P. R. China
/ Chaogui Lin
  • Department of Cardiology, Fujian Medical University Union Hospital; and Fujian Institute of Coronary Heart Disease, Fuzhou, P. R. China
/ Lin Fan
  • Department of Cardiology, Fujian Medical University Union Hospital; and Fujian Institute of Coronary Heart Disease, Fuzhou, P. R. China
Published Online: 2013-12-09 | DOI: https://doi.org/10.1515/cclm-2013-0844

Abstract

Background: Diabetes increases the risk and severity of atherosclerosis. Adropin, a metabolic homeostasis-related protein, has been implicated in the maintenance of metabolic homeostasis. We examined the relationship between serum adropin level and angiographic severity of coronary atherosclerosis in diabetic and non-diabetic patients.

Methods: A total of 392 patients with suspected coronary artery disease, who underwent coronary angiography, were assigned into the type 2 diabetic and non-diabetic groups and also classified into four groups according to the quartiles of adropin level. Venous serum samples were collected for adropin measurement by enzyme-linked immunosorbent assay and for biochemistry assay. The angiographic severity of coronary atherosclerosis was assessed by Gensini, Friesinger, and SYNTAX scores.

Results: Compared with non-diabetic patients, diabetic patients had lower serum adropin level and higher Gensini, Friesinger and SYNTAX scores (all p<0.001). Serum adropin level was inversely correlated with the Gensini, Friesinger and SYNTAX scores (rs=–0.389, –0.390 and –0.386, respectively, all p<0.001) among all patients. Low adropin level was an independent predictor of clinically relevant coronary atherosclerosis (SYNTAX score >11), both in diabetic patients [odds ratio (OR) 0.66, 95% confidence interval (CI) 0.53–0.83; p<0.001] and in non-diabetic patients (OR 0.51, 95% CI 0.35–0.74; p<0.001).

Conclusions: Serum adropin level was significantly lower in type 2 diabetic patients than in non-diabetic patients and was inversely and independently associated with angiographic severity of coronary atherosclerosis, suggesting that serum adropin serves as a novel predictor of coronary atherosclerosis.

Keywords: adropin; atherosclerosis; coronary artery disease; type 2 diabetes

References

  • 1.

    Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, et al., American Heart Association, American Diabetes Association. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007;115:114–26.

  • 2.

    Sanz J, Fuster V. The year in atherothrombosis. J Am Coll Cardiol 2011;58:779–91. [PubMed] [Crossref]

  • 3.

    Ford ES. Trends in the risk for coronary heart disease among adults with diagnosed diabetes in the U.S.: findings from the National Health and Nutrition Examination Survey, 1999–2008. Diabetes Care 2011;34:1337–43. [Web of Science]

  • 4.

    Mazzone T, Meyer PM, Kondos GT, Davidson MH, Feinstein SB, D′Agostino RB Sr, et al. Relationship of traditional and nontraditional cardiovascular risk factors to coronary artery calcium in type 2 diabetes. Diabetes 2007;56:849–55. [Crossref] [Web of Science]

  • 5.

    Avogaro A, Albiero M, Menegazzo L, de Kreutzenberg S, Fadini GP. Endothelial dysfunction in diabetes: the role of reparatory mechanisms. Diabetes Care 2011;34(Suppl 2):S285–90. [Crossref] [Web of Science]

  • 6.

    Versari D, Daghini E, Virdis A, Ghiadoni L, Taddei S. Endothelial dysfunction as a target for prevention of cardiovascular disease. Diabetes Care 2009;32(Suppl 2):S314–21. [Web of Science] [Crossref]

  • 7.

    Wagenknecht LE, Zaccaro D, Espeland MA, Karter AJ, O′Leary DH, Haffner SM. Diabetes and progression of carotid atherosclerosis: the insulin resistance atherosclerosis study. Arterioscler Thromb Vasc Biol 2003;23:1035–41. [PubMed] [Crossref]

  • 8.

    Kumar KG, Trevaskis JL, Lam DD, Sutton GM, Koza RA, Chouljenko VN, et al. Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism. Cell Metab 2008;8:468–81. [Web of Science] [PubMed] [Crossref]

  • 9.

    Lovren F, Pan Y, Quan A, Singh KK, Shukla PC, Gupta M, et al. Adropin is a novel regulator of endothelial function. Circulation 2010;122(Suppl):S185–92. [Crossref] [Web of Science]

  • 10.

    Ganesh Kumar K, Zhang J, Gao S, Rossi J, McGuinness OP, Halem HH, et al. Adropin deficiency is associated with increased adiposity and insulin resistance. Obesity (Silver Spring) 2012;20:1394–402. [Crossref]

  • 11.

    American Diabetes Association: diagnosis and classification of diabetes mellitus. Diabetes Care 2010;33(Suppl 1):S62–9.

  • 12.

    Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol 1983;51:606. [Crossref] [PubMed]

  • 13.

    Ringqvist I, Fisher LD, Mock M, Davis KB, Wedel H, Chaitman BR, et al. Prognostic value of angiographic indices of coronary artery disease from the coronary artery surgery study (CASS). J Clin Invest 1983;71:1854–66. [Crossref]

  • 14.

    Sianos G, Morel MA, Kappetein AP, Morice MC, Colombo A, Dawkins K, et al. The SYNTAX score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention 2005;1:219–27.

  • 15.

    Brugaletta S, Magro M, Simsek C, Heo JH, de Boer S, Ligthart J, et al. Plaque compositional Syntax score: combining angiography and lipid burden in coronary artery disease. JACC Cardiovasc Imaging 2012;5(Suppl 3):S119–21. [Web of Science]

  • 16.

    Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol 2010;56:1113–32. [Crossref]

  • 17.

    Bayturan O, Tuzcu EM, Lavoie A, Hu T, Wolski K, Schoenhagen P, et al. The metabolic syndrome, its component risk factors, and progression of coronary atherosclerosis. Arch Intern Med 2010;170:478–84. [PubMed] [Crossref]

  • 18.

    Butler AA, Tam CS, Stanhope KL, Wolfe BM, Ali MR, O′Keeffe M, et al. Low circulating adropin concentrations with obesity and aging correlate with risk factors for metabolic disease and increase after gastric bypass surgery in humans. J Clin Endocrinol Metab 2012;97:3783–91. [Crossref]

  • 19.

    Heitzer T, Schlinzig T, Krohn K, Meinertz T, Münzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001;104:2673–8. [Crossref] [PubMed]

  • 20.

    Laakso M. Cardiovascular disease in type 2 diabetes from population to man to mechanisms: the Kelly West Award Lecture 2008. Diabetes Care 2010;33:442–9. [Web of Science]

  • 21.

    Celik E, Yilmaz E, Celik O, Ulas M, Turkcuoglu I, Karaer A, et al. Maternal and fetal adropin levels in gestational diabetes mellitus. J Perinat Med 2013;9:1–6. [Web of Science]

  • 22.

    Celik A, Balin M, Kobat MA, Erdem K, Baydas A, Bulut M, et al. Deficiency of a new protein associated with cardiac syndrome X; called adropin. Cardiovasc Ther 2013;31:174–8. [PubMed] [Crossref] [Web of Science]

  • 23.

    Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003;107:363–9. [PubMed] [Crossref]

  • 24.

    Jager A, van Hinsbergh VW, Kostense PJ, Emeis JJ, Yudkin JS, Nijpels G, et al. von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the Hoom Study. Arterioscler Thromb Vasc Biol 1999;19:3071–8.

  • 25.

    Taniguchi H, Momiyama Y, Ohmori R, Yonemura A, Yamashita T, Tamai S, et al. Associations of plasma C-reactive protein levels with the presence and extent of coronary stenosis in patients with stable coronary artery disease. Atherosclerosis 2005;178:173–7. [Crossref]

  • 26.

    Noren Hooten N, Ejiogu N, Zonderman AB, Evans MK. Association of oxidative DNA damage and C-reactive protein in women at risk for cardiovascular disease. Arterioscler Thromb Vasc Biol 2012;32:2776–84. [Crossref] [Web of Science] [PubMed]

About the article

Corresponding author: Lianglong Chen, Department of Cardiology, Fujian Medical University Union Hospital, 29 Xin-Quan Road, 350001, Fuzhou, Fujian, P.R China, Phone/Fax: +86 591 83342282, E-mail:


Received: 2013-10-03

Accepted: 2013-11-18

Published Online: 2013-12-09

Published in Print: 2014-05-01



Citation Information: Clinical Chemistry and Laboratory Medicine, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/cclm-2013-0844. Export Citation

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Liang Li, Wei Xie, Xi-Long Zheng, Wei-Dong Yin, and Chao-Ke Tang
Clinica Chimica Acta, 2015
[2]
Liang-Ping Zhao, Wei-Ting Xu, Li Wang, Tao You, Siew-Pang Chan, Xin Zhao, and Xiang-Jun Yang
Heart, Lung and Circulation, 2015
[3]
Su Gao, Ryan P. McMillan, Qingzhang Zhu, Gary D. Lopaschuk, Matthew W. Hulver, and Andrew A. Butler
Molecular Metabolism, 2015, Volume 4, Number 4, Page 310
[4]
Hou-you Yu, Peng Zhao, Ming-chun Wu, Jian Liu, and Wen Yin
Regulatory Peptides, 2014, Volume 190-191, Page 46

Comments (0)

Please log in or register to comment.
Log in